RBC Capital analyst Leonid Timashev initiated coverage of Revolution Medicines (RVMD) with an Outperform rating and $77 price target The firm believes Revolution is best positioned to execute on targeting RAS across oncology, given its “impressive” efficacy data, development lead, and pipeline. RBC thinks the company’s Phase III readout in 2026 is “highly likely to hit.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
- Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers
- Revolution Medicines Advances RAS(ON) Inhibitors in NSCLC Study
- Revolution Medicines’ RASolve 301 Study: A Potential Game-Changer for NSCLC Treatment
- Revolution Medicines Advances Phase 3 Trial for Pancreatic Cancer Treatment